Publications by authors named "Amy Newton"

Claim this Profile
D
Domestic Violence and Pregnancy: A CBPR Coalition Approach to Identifying Needs and Informing Policy.
Candace Forbes Bright, Braden Bagley, Ivie Pulliam, Amy Swetha Newton

Prog Community Health Partnersh· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective Na1.7 Inhibitors for the Treatment of Pain.
Guanglin Luo, Ling Chen, Amy Easton, Amy Newton, Clotilde Bourin

J Med Chem· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective Na1.7 Inhibitors for the Treatment of Pain.
Guanglin Luo, Ling Chen, Amy Easton, Amy Newton, Clotilde Bourin

J Med Chem· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characterization of ()-3-((3,4)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate -Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder.
Linda J Bristow, Jyoti Gulia, Michael R Weed, Bettadapura N Srikumar, Yu-Wen Li, Amy Newton

J Pharmacol Exp Ther· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of non-zwitterionic aryl sulfonamides as Na1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation.
Yong-Jin Wu, Jason Guernon, Andrea McClure, Guanglin Luo, Ramkumar Rajamani, Amy Newton

Bioorg Med Chem· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of New Benzenesulfonamides As Potent and Selective Na1.7 Inhibitors for the Treatment of Pain.
Yong-Jin Wu, Jason Guernon, Jianliang Shi, Jonathan Ditta, Kevin J Robbins, Amy Newton

J Med Chem· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Indazoles as Potent, Orally Active Dual Neurokinin 1 Receptor Antagonists and Serotonin Transporter Inhibitors for the Treatment of Depression.
Andrew P Degnan, George O Tora, Hong Huang, David A Conlon, Carl D Davis, Amy E Newton

ACS Chem Neurosci· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The host immune response in respiratory virus infection: balancing virus clearance and immunopathology.
Amy H Newton, Amber Cardani, Thomas J Braciale

Semin Immunopathol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timely blockade of ICAM-1.LFA-1 interaction prevents disease onset in a mouse model of emphysema.
Amy H Newton, Derek B Danahy, Marcia A Chan, Stephen H Benedict

Immunotherapy· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of in vivo [(3)H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice.
Alda Fernandes, Trevor Wojcik, Praveena Baireddy, Rick Pieschl, Amy Newton

Eur J Pharmacol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus.
John D Graef, Kimberly Newberry, Amy Newton, Rick Pieschl, Eric Shields

Brain Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical risk factors for preeclampsia in the 21st century.
Emmanuelle Paré, Samuel Parry, Thomas F McElrath, Dominick Pucci, Amy Newton

Obstet Gynecol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low density lipoprotein promotes human naive T cell differentiation to Th1 cells.
Amy H Newton, Stephen H Benedict

Hum Immunol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a cyclopentylamine as an orally active dual NK1 receptor antagonist-serotonin reuptake transporter inhibitor.
Yong-Jin Wu, Huan He, Qi Gao, Dedong Wu, Robert Bertekap, Amy Newton

Bioorg Med Chem Lett· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test.
Snjezana Lelas, Yu-Wen Li, Tanya L Wallace-Boone, Matthew T Taber, Amy E Newton

Neuropharmacology· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.
Yong-Jin Wu, Huan He, Robert Bertekap, Ryan Westphal, Snjezana Lelas, Amy Newton

Bioorg Med Chem· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression.
Kevin W Gillman, Michael F Parker, Mark Silva, Andrew P Degnan, George O Tora, Amy E Newton

Bioorg Med Chem Lett· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Behavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists.
Tanya L Wallace-Boone, Amy E Newton, Robert N Wright, Nicholas J Lodge, John F McElroy

Neuropsychopharmacology· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition.
Yong-Jin Wu, Carl D Davis, Steven Dworetzky, William C Fitzpatrick, David Harden, Amy E Newton

J Med Chem· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(S)-N-[1-(3-morpholin-4-ylphenyl)ethyl]- 3-phenylacrylamide: an orally bioavailable KCNQ2 opener with significant activity in a cortical spreading depression model of migraine.
Yong-Jin Wu, Christopher G Boissard, Corinne Greco, Valentin K Gribkoff, David G Harden, Amy E Newton

J Med Chem· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis